Skip to content
GLP1-US
Prices checked Wegovy pill $149 Wegovy pen $349 Zepbound $299–449 Foundayo from $149 Ozempic $349 Medicare Bridge $50 Compounded sema $175 All prices →

Safety guide · Wegovy label rev. 06/2026

Wegovy Side Effects, Rate by Rate: Pen, HD and Pill

Nausea is the most common Wegovy side effect: 44% on the 2.4 mg pen vs 16% on placebo, and 39% on 7.2 mg. Most stomach effects show up while the dose is stepped up.

  • Top 5 are all digestive
  • 6.8% stopped for side effects vs 3.2%
  • Boxed warning: thyroid C-cell tumors
  • Pill: severe GI 2% vs 0%

We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure

By GLP1-US Editorial TeamUpdated
★ Editor's Choice
Chia Health logo

Chia Health

Our #1 pick for GLP-1 weight loss online

  • One monthly price: clinician, medication and free shipping included
  • Semaglutide or tirzepatide, as a weekly injection or a daily tablet
  • No insurance needed; HSA/FSA and Klarna accepted

Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure

$212.89 first month, then $349/mo

6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.

Get Started Read our Chia Health review

01 Most common

Common Wegovy Side Effects on the 2.4 mg Pen

Wegovy is semaglutide, a once-weekly injection (and a daily tablet) for weight reduction and heart-risk reduction. The label lists 19 reactions seen in at least 2% of adults on the 2.4 mg pen and more often than on placebo. Most are digestive, which fits how semaglutide works: it slows how fast the stomach empties.

Side effectPlacebo (N=1,261)Wegovy 2.4 mg (N=2,116)
Nausea 16% 44%
Diarrhea 16% 30%
Vomiting 6% 24%
Constipation 11% 24%
Abdominal pain 10% 20%
Headache 10% 14%
Fatigue 5% 11%
Dyspepsia (indigestion) 3% 9%
Dizziness 4% 8%
Abdominal distension 5% 7%
Belching <1% 7%
Low blood sugar, type 2 diabetes only 2% 6%
Gas (flatulence) 4% 6%
Hair loss 1% 3%

Label 6.1, Table 3 Also in the table: gastroenteritis 6% vs 4%, reflux 5% vs 3%, gastritis 4% vs 1%, viral gastroenteritis 4% vs 3%, dysesthesia 2% vs 1%. Vomiting is 24% in Table 3 and 25% in the label's text summary of stomach reactions; this page uses the table.

Across the three trials, 6.8% on Wegovy and 3.2% on placebo stopped for side effects, most often for nausea (1.8% vs 0.2%), vomiting (1.2% vs 0%) and diarrhea (0.7% vs 0.1%). For scale, the same label reports 14.9% average weight loss at week 68 in the main pen trial (STEP 1) vs 2.4% on placebo.

02 Wegovy HD

Wegovy HD 7.2 mg Side Effects vs 2.4 mg

Wegovy HD is the 7.2 mg weekly dose. Its safety data come from two 72-week trials with 1,311 adults on 7.2 mg, 304 on 2.4 mg and 303 on placebo. The chart shows reactions that were at least 2% and more common on 7.2 mg than on both other arms.

Label 6.1, Table 4

  • Dysesthesia is the HD signal. Burning, tingling or sensitive skin: 22% on 7.2 mg vs 6% on 2.4 mg and 0.3% on placebo. Of 288 people who had it on 7.2 mg, 2% stopped, 8% paused and 23% lowered the dose; 18% had not recovered by the end of the trial. Of 38 who recovered and went back to 7.2 mg, 17 (45%) had it again.
  • Stopping was the same on both doses. 5% on 7.2 mg, 5% on 2.4 mg and 2% on placebo stopped because of side effects, mostly stomach-related (3%, 3%, 0.3%).

Weight loss in the same trial program: 18.8% on 7.2 mg vs 15.5% on 2.4 mg and 3.9% on placebo at week 72. Dosing and price: Wegovy HD 7.2 mg.

03 Wegovy pill

Wegovy Pill (25 mg Tablet) Side Effects vs the Pen

The label has no separate side-effect table for the tablet. It says the types and frequency of common reactions on 25 mg were similar to the pen's Table 3. The tablet trial (OASIS 4) had 204 adults on 25 mg for 64 weeks and excluded people with type 2 diabetes. Where the label splits the numbers, they are below.

Severe stomach reactions
2% vs 0%
tablet vs placebo; pen 4.1% vs 0.9% 5.6, 6.1
Gallstones
2.5% vs 1%
tablet vs placebo; pen 1.6% vs 0.7% 5.3, 6.1
Dysesthesia
5% vs 0%
tablet vs placebo; 2.4 mg pen 6%, 7.2 mg pen 22% 6.1
Stopped for any side effect
6.9% vs 5.9%
tablet vs placebo; pen 6.8% vs 3.2% 6.1
Stopped for stomach reasons
3.4% vs 2%
tablet vs placebo 6.1
Average weight loss
13.6%
tablet, 64 weeks, placebo 2.4%; pen 14.9% at 68 weeks 14.2

The tablet is taken on an empty stomach in the morning with up to 4 ounces of plain water; wait at least 30 minutes before eating, drinking or taking other oral medicines. Details: Wegovy pill and Wegovy pill vs injection.

04 Timing

When Wegovy Side Effects Happen and How Long They Last

  1. 1

    Weeks 1 to 4. 0.25 mg pen once a week, or 1.5 mg tablet once a day. Mild nausea or fullness is the usual report. Smaller meals and steady fluids help.

  2. 2

    Each dose step. The pen goes 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg, one step every 4 weeks. The label says stomach reactions were most often reported during escalation, so expect a flare around a step.

  3. 3

    If a step is not tolerated. The label lets the prescriber delay the next increase by 4 weeks. That is a clinician decision, not one to make alone.

  4. 4

    Maintenance. 2.4 mg pen (or 7.2 mg HD) or 25 mg tablet. The label gives no day count for how long nausea lasts, so this page does not claim one.

  5. 5

    Effects that will not settle. Vomiting or diarrhea that keeps going risks dehydration and kidney injury. Call your prescriber (see below).

Label 2.2, 2.3, 6.1

Food and timing tips beyond the label: how to handle GLP-1 nausea. Every dose step: Wegovy dosage.

05 Warnings

Serious Wegovy Warnings, With the Numbers

These are the warnings in section 5 of the label. Each is uncommon; each has a symptom pattern worth knowing.

Pancreatitis

Severe belly pain that will not go away, sometimes through to the back, with or without vomiting. Confirmed in 4 Wegovy patients (0.2 per 100 patient-years) vs 1 on placebo. Stop Wegovy if suspected. 5.2, 6.1

Gallbladder disease

Upper belly pain, fever, yellow skin or eyes, clay-colored stools. Gallstones 1.6% on the pen vs 0.7%, 2.5% on the tablet vs 1%; cholecystitis 0.6% vs 0.2%. 5.3, 6.1

Severe stomach reactions

4.1% on the pen vs 0.9%; 2% on the tablet vs 0%. Not recommended with severe gastroparesis. Ileus, bowel obstruction and fecal impaction appear in postmarketing reports. 5.6, 6.2

Kidney injury

7 adults on Wegovy (0.4 per 100 patient-years) vs 4 on placebo (0.2), some linked to vomiting, diarrhea or dehydration. Keep fluids up. 5.5, 6.1

Low blood sugar

Mainly in type 2 diabetes: below 54 mg/dL in 6.2% on the pen vs 2.5% on placebo, and higher with a sulfonylurea or insulin. 5.4, 6.1

Allergic reactions

Anaphylaxis and angioedema have been reported. Stop Wegovy and get help right away. 5.7

Eyes in type 2 diabetes

Diabetic retinopathy in 4% on the pen vs 2.7% on placebo in the diabetes trial. Fast sugar improvement can briefly worsen it. 5.8, 6.1

Heart rate

Average rise of 1 to 4 beats a minute; a peak rise of 20 or more in 26% vs 16% on placebo. Report a racing heart at rest. 5.9, 6.1

Surgery and sedation

Rare reports of food aspirated into the lungs under anesthesia. Tell your surgeon and anesthesia team you take Wegovy. 5.10

Never share a pen

A Wegovy FlexTouch pen is for one person only, even with a new needle, because of infection risk. 5.11

06 Boxed warning

Boxed Warning: Thyroid C-Cell Tumors

Wegovy carries the FDA's boxed warning for thyroid C-cell tumors. In rats and mice, semaglutide caused these tumors at clinically relevant exposures. The label says it is unknown whether Wegovy causes them, including medullary thyroid carcinoma (MTC), in people.

  • Do not use Wegovy with a personal or family history of MTC, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Report a lump in the neck, trouble swallowing, shortness of breath or hoarseness that does not go away.

Routine calcitonin tests or thyroid ultrasound are of uncertain value for early detection, per the label. (Boxed Warning, 4, 5.1)

07 Red flags

When to Call a Doctor or Get Emergency Help

Get help right away

  • Swelling of the face, lips, tongue or throat, trouble breathing or swallowing, severe rash, fainting (stop Wegovy)
  • Severe belly pain that will not go away, with or without vomiting, sometimes felt in the back (stop Wegovy)
  • Too much Wegovy: severe nausea, vomiting or low blood sugar. Poison Help 1-800-222-1222 or the nearest ER

Call your prescriber soon

  • Nausea, vomiting or diarrhea that does not go away
  • Upper belly pain, fever, yellow skin or eyes, clay-colored stools
  • Low blood sugar signs with type 2 diabetes: shakiness, sweating, confusion, fast heartbeat
  • Vision changes if you have type 2 diabetes
  • A racing heart at rest that lasts several minutes
  • A neck lump, trouble swallowing, lasting hoarseness
  • Any planned surgery, colonoscopy or sedation

Report side effects to the FDA at 1-800-FDA-1088 (MedWatch). A clinician who knows your history should decide about dose changes or stopping. Medication Guide

Ro prescribes the Wegovy pen, Wegovy HD and the Wegovy pill, with clinician follow-up for side-effect questions and dose changes during titration.

See Wegovy eligibility with Ro

08 Other effects

Other Side Effects the Label Lists

Hair loss
2.4 mg pen: 3.3% (4% of women, 0.9% of men) vs 1% on placebo. 7.2 mg: 5.8% (8.4% of women, 0.2% of men). The label links it to weight reduction. 6.1
Low blood pressure, fainting
hypotension 1.3% vs 0.4%; fainting 0.8% vs 0.2%, more often with blood pressure medicines. 6.1
Appendicitis
10 patients (0.5%) vs 2 (0.2%) on placebo. 6.1
Injection-site reactions
1.4% vs 1% (itching, redness, irritation). 6.1
Taste change
dysgeusia 1.7% vs 0.5%. 6.1
Fractures
in the heart-outcomes trial, hip and pelvis fractures in women: 1% (24 of 2,448) vs 0.2% (5 of 2,424). 6.1
Kidney stones
urolithiasis 1.2% vs 0.8% in the heart-outcomes trial. 6.1
Lab changes
amylase up 15% to 16% and lipase up 39% on average; meaning unknown without other signs of pancreatitis. 6.1
Pregnancy
stop Wegovy at least 2 months before a planned pregnancy. Pregnancy registry: 1-877-390-2760. 8.1

The years-long picture (heart-outcomes trial, regain after stopping): GLP-1 long-term side effects. Same molecule, diabetes brand: Ozempic side effects. Tirzepatide for comparison: Mounjaro side effects.

09 Label change

FDA Removed the Suicidality Warning in January 2026

  1. Jan 13, 2026

    The FDA asked the makers of Wegovy, Saxenda and Zepbound to remove the suicidal behavior and ideation warning after its review found no increased risk, including a meta-analysis of 91 placebo-controlled trials with 107,910 participants.

  2. Label rev. 06/2026

    The Wegovy label lists "Suicidal Behavior and Ideation (Removed) 01/2026". The thyroid boxed warning is unchanged.

Older pages that still describe a suicidality warning on Wegovy are out of date. Mood changes are still worth mentioning to your clinician.

10 FAQ

Wegovy Side Effects FAQ

What are the most common Wegovy side effects?
On the 2.4 mg pen: nausea 44% vs 16% on placebo, diarrhea 30% vs 16%, vomiting 24% vs 6%, constipation 24% vs 11% and abdominal pain 20% vs 10%. Headache (14%) and fatigue (11%) follow. The label says stomach effects were most often reported while the dose was being stepped up. Source: Wegovy label 6.1, Table 3, rev. 06/2026.
Does the Wegovy pill have the same side effects as the pen?
The label says the types and frequency of common reactions on the 25 mg tablet were similar to the pen. Where it splits them: severe stomach reactions 2% vs 0% on placebo (pen 4.1% vs 0.9%), gallstones 2.5% vs 1% (pen 1.6% vs 0.7%) and dysesthesia 5% vs 0%. In the tablet trial, 6.9% stopped for side effects vs 5.9% on placebo.
Are Wegovy HD (7.2 mg) side effects worse?
Some are higher. In the 72-week trials, nausea was 39% on 7.2 mg vs 35% on 2.4 mg, vomiting 22% vs 16%, and dysesthesia (skin burning or tingling) 22% vs 6%. Hair loss was 6% vs 3%. The share who stopped because of side effects was 5% on both doses. Source: label 6.1, Table 4.
Does Wegovy cause hair loss?
It can. In the 2.4 mg pen trials, hair loss was 3.3% vs 1% on placebo: 4% of women and 0.9% of men. At 7.2 mg it was 5.8% overall and 8.4% in women. The label links hair loss to weight reduction. Source: label 6.1.
Can Wegovy cause thyroid cancer?
Semaglutide caused thyroid C-cell tumors in rats and mice, which is why the label carries a boxed warning. It is unknown whether Wegovy causes these tumors, including medullary thyroid carcinoma, in people. Do not use it with a personal or family history of MTC or MEN 2, and report a neck lump, hoarseness or trouble swallowing.
When should I stop Wegovy and call a doctor?
Stop and get help right away for signs of a serious allergic reaction (face or throat swelling, trouble breathing) or severe belly pain that will not go away, which may be pancreatitis. Call your prescriber soon for vomiting or diarrhea that persists, upper belly pain with fever or yellow skin, or a racing heart at rest.
Does Wegovy still have a suicide warning?
No. On Jan 13, 2026 the FDA asked for the suicidal behavior and ideation warning to be removed from Wegovy, Saxenda and Zepbound after a review found no increased risk. The 06/2026 Wegovy label lists that section as removed in 01/2026. The thyroid boxed warning remains. Mood changes are still worth raising with your clinician.

All GLP-1 safety info in one place: GLP-1 side effects and safety hub.

Prices for every Wegovy form: Wegovy cost. Brand overview: Wegovy guide.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.

Last updated Oct 29, 2026 · Side-effect rates checked against the Wegovy label (injection and tablets, rev. 06/2026). This page is not medical advice; talk to your healthcare provider about your own risks.

Checked against primary sources such as FDA labels, CMS and provider pages
Updated
How we check facts →